ACUC Stock Overview
Develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AcuCort AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.86 |
| 52 Week High | kr1.45 |
| 52 Week Low | kr0.33 |
| Beta | 0.87 |
| 1 Month Change | 33.96% |
| 3 Month Change | 107.73% |
| 1 Year Change | -37.68% |
| 3 Year Change | -81.86% |
| 5 Year Change | -86.77% |
| Change since IPO | -82.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACUC | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -2.3% | -2.0% | -0.8% |
| 1Y | -37.7% | 82.0% | 12.8% |
Return vs Industry: ACUC underperformed the Swedish Pharmaceuticals industry which returned 82% over the past year.
Return vs Market: ACUC underperformed the Swedish Market which returned 12.8% over the past year.
Price Volatility
| ACUC volatility | |
|---|---|
| ACUC Average Weekly Movement | 16.6% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ACUC's share price has been volatile over the past 3 months.
Volatility Over Time: ACUC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 3 | Jonas Jonmark | www.acucort.com |
AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
AcuCort AB (publ) Fundamentals Summary
| ACUC fundamental statistics | |
|---|---|
| Market cap | kr102.49m |
| Earnings (TTM) | -kr13.87m |
| Revenue (TTM) | kr6.81m |
15.1x
P/S Ratio-7.4x
P/E RatioIs ACUC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACUC income statement (TTM) | |
|---|---|
| Revenue | kr6.81m |
| Cost of Revenue | kr15.30m |
| Gross Profit | -kr8.49m |
| Other Expenses | kr5.39m |
| Earnings | -kr13.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | -124.71% |
| Net Profit Margin | -203.80% |
| Debt/Equity Ratio | 0% |
How did ACUC perform over the long term?
See historical performance and comparison